SCHEMBL2397119

SCHEMBL2397119

C=CCN(Cc1ccc(C(C)C)cc1)C(=O)c1ncn(-c2cc(Cl)c(O)c(Cl)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.36
HDAC1 Q13547 3/20 0.32
HDAC6 Q9UBN7 3/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 3/20 0.31
MAPT P10636 3/20 0.31
POLB P06746 1/20 0.31
HSP90AA1 P07900 2/20 0.31
THRB P10828 1/20 0.31
HSP90AB1 P08238 1/20 0.31
GAA P10253 1/20 0.31
MELK Q14680 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398428 0.89 NOTUM (0.39) NOTUMHDAC1HDAC6TP53MAPT
SCHEMBL2400858 0.88 NOTUM (0.36) NOTUMKMT2ATP53MAPTTHRB
SCHEMBL2399545 0.88 NOTUM (0.43) NOTUMKMT2A
SCHEMBL2218692 0.88 HDAC1 (0.42) NOTUMHDAC1HDAC6KMT2ATP53
SCHEMBL2399028 0.85 LPAR1 (0.37) NOTUMKMT2AMAPTPOLB
SCHEMBL2214594 0.84 NOTUM (0.39) NOTUMHDAC6KMT2ATP53MAPT
SCHEMBL2186910 0.82 NOTUM (0.43) NOTUMTP53MAPTPOLBGAA
SCHEMBL2401803 0.80 HSD17B13 (0.38) MAPT
SCHEMBL2399616 0.78 SLC6A9 (0.42)
SCHEMBL2215745 0.77 NOTUM (0.48) NOTUMHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US claimed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives CFTR, PKD1, PKD2 NOTUM 3691/4885HDAC1 2458/4885HDAC6 829/4885
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES CFTR, PKD1, PKD2 NOTUM 3951/4885HDAC1 1369/4885HDAC6 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.